About: Sensitization of (colon) cancer cells to death receptor related therapies A report from the FP6-ONCODEATH research consortium

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Sensitization of (colon) cancer cells to death receptor related therapies A report from the FP6-ONCODEATH research consortium Goto Sponge NotDistinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/domain/vavai/Vysledek, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	skos:Concept http://linked.opendata.cz/ontology/domain/vavai/Vysledek
Description	The objective of the ONCODEATH consortium [EU Research Consortium %22ONCODEATH%22 (2006-2010)] was to achieve sensitization of solid tumor cells to death receptor related therapies using rational mechanism-based drug combinations of targeted therapies. In this collaborative effort, during a period of 42 months, cell and animal model systems of defined oncogenes were generated. Exploitation of generated knowledge and tools enabled the consortium to achieve the following research objectives: (1) elucidation of tumor components which confer sensitivity or resistance to TRAIL-induced cell death; (2) providing detailed knowledge on how small molecule Hsp90, Aurora, choline kinase, BRAF inhibitors, DNA damaging agents, HDAC and DNMT inhibitors affect the intrinsic apoptotic amplification and execution machineries; (3) optimization of combined action of TRAIL with these therapeutics for optimum effects with minimum concentrations and toxicity in vivo. These findings provide mechanistic basis for a pharmacogenomic approach, which could be exploited further therapeutically, in order to reach novel personalized therapies for cancer patients. The objective of the ONCODEATH consortium [EU Research Consortium %22ONCODEATH%22 (2006-2010)] was to achieve sensitization of solid tumor cells to death receptor related therapies using rational mechanism-based drug combinations of targeted therapies. In this collaborative effort, during a period of 42 months, cell and animal model systems of defined oncogenes were generated. Exploitation of generated knowledge and tools enabled the consortium to achieve the following research objectives: (1) elucidation of tumor components which confer sensitivity or resistance to TRAIL-induced cell death; (2) providing detailed knowledge on how small molecule Hsp90, Aurora, choline kinase, BRAF inhibitors, DNA damaging agents, HDAC and DNMT inhibitors affect the intrinsic apoptotic amplification and execution machineries; (3) optimization of combined action of TRAIL with these therapeutics for optimum effects with minimum concentrations and toxicity in vivo. These findings provide mechanistic basis for a pharmacogenomic approach, which could be exploited further therapeutically, in order to reach novel personalized therapies for cancer patients. (en)
Title	Sensitization of (colon) cancer cells to death receptor related therapies A report from the FP6-ONCODEATH research consortium Sensitization of (colon) cancer cells to death receptor related therapies A report from the FP6-ONCODEATH research consortium (en)
skos:prefLabel	Sensitization of (colon) cancer cells to death receptor related therapies A report from the FP6-ONCODEATH research consortium Sensitization of (colon) cancer cells to death receptor related therapies A report from the FP6-ONCODEATH research consortium (en)
skos:notation	RIV/68378050:_____/12:00387575!RIV13-AV0-68378050
http://linked.open...avai/riv/aktivita	I
http://linked.open...avai/riv/aktivity	I
http://linked.open...iv/cisloPeriodika	7
http://linked.open...vai/riv/dodaniDat	2013
http://linked.open...aciTvurceVysledku	Anděra, Ladislav
http://linked.open.../riv/druhVysledku	J - Článek v odborném periodiku
http://linked.open...iv/duvernostUdaju	S - Úplné a pravdivé údaje nepodléhající ochraně podle zvláštních právních předpisů
http://linked.open...titaPredkladatele	Ústav molekulární genetiky AV ČR, v. v. i.
http://linked.open...dnocenehoVysledku	167454
http://linked.open...ai/riv/idVysledku	RIV/68378050:_____/12:00387575
http://linked.open...riv/jazykVysledku	eng - angličtina
http://linked.open.../riv/klicovaSlova	cancer; death receptors; kinase inhibitors; mitochondria; targeted therapies (en)
http://linked.open.../riv/klicoveSlovo	cancer mitochondria death receptors kinase inhibitors targeted therapies
http://linked.open...odStatuVydavatele	US - Spojené státy americké
http://linked.open...ontrolniKodProRIV	[0C17021D8133]
http://linked.open...i/riv/nazevZdroje	Cancer Biology & Therapy
http://linked.open...in/vavai/riv/obor	EB
http://linked.open...ichTvurcuVysledku	1 (xsd:int)
http://linked.open...cetTvurcuVysledku	10 (xsd:int)
http://linked.open...UplatneniVysledku	2012
http://linked.open...v/svazekPeriodika	13
http://linked.open...iv/tvurceVysledku	Anděra, Ladislav Pintzas, A. Zhivotovsky, B. Clarke, P. A. Lacal, J. C. Linardopoulos, S. Martinou, J. C. Nasioulas, G. Robine, S. Workman, P.
http://linked.open...ain/vavai/riv/wos	000303927700002
issn	1538-4047
number of pages	9 (xsd:int)
http://bibframe.org/vocab/doi	10.4161/cbt.19600

Faceted Search & Find service v1.16.118 as of Jun 21 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 67 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software